Medicare Proposes Expanded Coverage and New Studies of FDG-PET for the Diagnosis Alzheimer's Disease

July 17, 2004

Medicare Proposes Expanded Coverage and New Studies of FDG-PET for the Diagnosis Alzheimer's Disease

CMS determined that use of PET for the diagnosis of suspected AD would be covered for patients when a specific diagnosis remains uncertain despite a thorough clinical evaluation. Medicare will also cover PET in other patients with early dementia or unexpected memory loss who are enrolled in clinical trials with certain safeguards for patients, including informed individualized analysis and evaluation of test results and health status.

CMS will accept public comments on the draft decision memorandum for 30 days, and will make the decision final within 90 days.